Drug Trial Radar · NCT00853242
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
Last checked: Nov 20, 2026Latest source record: May 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
349
Actual
Start
Feb 2009
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.
Conditions
- Kidney Failure, Chronic
Interventions
PlaceboDrug
Genz-644470Drug
Sevelamer carbonateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo)Time frame: Baseline, Day 22
Locations
53 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Alexander City, Alabama
Site not named
Birmingham, Alabama
Site not named
Hot Springs, Arkansas
Site not named
Bakersfield, California
Site not named
Los Angeles, California
Site not named
Paramount, California
Site not named
Pembroke Pines, California
Site not named
Porterville, California
Site not named
Riverside, California
Site not named
San Dimas, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Hudson, Florida
Site not named
Ocala, Florida
Site not named
Tampa, Florida
Site not named
Augusta, Georgia
Site not named
Marietta, Georgia
Site not named
Gurnee, Illinois
Site not named
Indianapolis, Indiana
Site not named
Wichita, Kansas
Site not named
Lexington, Kentucky
Site not named
Bethesda, Maryland
Site not named
Pontiac, Michigan
Site not named
Southfield, Michigan
Site not named
Brookhaven, Mississippi
Site not named
Gulfport, Mississippi
Site not named
St Louis, Missouri
Site not named
Kearney, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Bellmore, New York
Site not named
Brooklyn, New York
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Port Washington, New York
Site not named
The Bronx, New York
Site not named
Asheville, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Doylestown, Pennsylvania
Site not named
Lancaster, Pennsylvania
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.